More on Vivus earnings

|By:, SA News Editor

Vivus (VVUS) Q2 comes in below estimates.

Net product revenue was $5.5M, versus a flatline last year.

Net losses increased Y/Y, primarily due to increased SG&A expenses related to commercialization activities for Qsymia.

Approximately 81K Qsymia prescriptions were dispensed during the quarter, of which approximately 24K were dispensed under the Free Trial Offer.

All of these prescriptions were dispensed through the certified mail order home delivery system.

Shares unchanged AH.